PathPresenter introduces ConsultConnect, a zero footprint web portal for remote second opinions

PathPresenter, a leader in digital pathology workflow software, is pleased to announce ConsultConnect, a new solution for digital pathology consultations and remote second opinions.

Vertex’s non-opioid pain drug is approved by FDA, bringing first of new class to market

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

February 1, 2025

High blood pressure in kids doubles their risk of cardiovascular disease, study finds, bringing a call for routine screening

Children and adolescents diagnosed with high blood pressure have double the risk of major cardiovascular problems as adults, a new study that followed them into

May 6, 2024

Mipasetamab uzoptirine by ADC Therapeutics for Malignant Fibrous Histiocytoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.